Literature DB >> 24766800

Mutant PTEN in Cancer: Worse Than Nothing.

Nick R Leslie1, Jeroen den Hertog2.   

Abstract

Tumor suppressors block the development of cancer and are often lost during tumor development. Papa et al. show that partial loss of normal PTEN tumor suppressor function can be compounded by additional disruption caused by the expression of inactive mutant PTEN protein. This has significant implications for patients with PTEN gene mutations.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24766800     DOI: 10.1016/j.cell.2014.04.008

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  5 in total

1.  The PTEN Tumor Suppressor Forms Homodimers in Solution.

Authors:  Frank Heinrich; Srinivas Chakravarthy; Hirsh Nanda; Antonella Papa; Pier Paolo Pandolfi; Alonzo H Ross; Rakesh K Harishchandra; Arne Gericke; Mathias Lösche
Journal:  Structure       Date:  2015-08-20       Impact factor: 5.006

2.  Molecular Characterization of the Dominant-Negative Role of Cancer-Associated PTEN: Sometimes, Null is Better.

Authors:  Saverio Marchi; Paolo Pinton
Journal:  Front Oncol       Date:  2014-10-10       Impact factor: 6.244

3.  The Die Is Cast: Precision Electrophilic Modifications Contribute to Cellular Decision Making.

Authors:  Marcus J C Long; Yimon Aye
Journal:  Chem Res Toxicol       Date:  2016-10-02       Impact factor: 3.739

4.  Decreased expression of pseudogene PTENP1 promotes malignant behaviours and is associated with the poor survival of patients with HNSCC.

Authors:  Jiannan Liu; Yue Xing; Liqun Xu; Wantao Chen; Wei Cao; Chenping Zhang
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

Review 5.  Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets.

Authors:  Alexandros Karagiannakos; Maria Adamaki; Antonis Tsintarakis; Borek Vojtesek; Robin Fåhraeus; Vassilis Zoumpourlis; Konstantinos Karakostis
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.